Frédéric Jacotot
General Counsel at VALNEVA
Net worth: 998 052 $ as of 2024-04-29
Frédéric Jacotot active positions
Companies | Position | Start | End |
---|---|---|---|
VALNEVA | General Counsel | 2017-03-31 | - |
Corporate Secretary | 2017-03-31 | - | |
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Director/Board Member | 2017-05-31 | - |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Director/Board Member | 2017-05-31 | - |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Chief Executive Officer | 2017-08-31 | - |
Career history of Frédéric Jacotot
Former positions of Frédéric Jacotot
Companies | Position | Start | End |
---|---|---|---|
Abbott Laboratories, Inc.
Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the private company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Corporate Officer/Principal | 2010-08-31 | 2013-07-31 |
Training of Frédéric Jacotot
Université Paris 1 Panthéon-Sorbonne | Graduate Degree |
Statistics
International
France | 3 |
Sweden | 3 |
Austria | 2 |
Operational
Director/Board Member | 2 |
General Counsel | 1 |
Corporate Secretary | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
VALNEVA | Health Technology |
Private companies | 4 |
---|---|
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The private company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The private company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
Abbott Laboratories, Inc.
Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the private company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Health Technology |
Valneva Sweden AB
Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The private company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Health Technology |
- Stock Market
- Insiders
- Frédéric Jacotot
- Experience